Overview

The Effect of Tranexamic Acid on Blood Loss and Transfusion Requirements Following Open Femur Fracture Surgery

Status:
Withdrawn
Trial end date:
2021-04-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to determine the effect of tranexamic acid (TXA) on blood loss and transfusion requirements in patients with femur fractures requiring open surgical approaches.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
The University of Texas Health Science Center, Houston
Treatments:
Anesthetics
Tranexamic Acid
Criteria
Inclusion Criteria:

- Patients admitted to Memorial Hermann Medical Center with acute femur fractures that
require open surgical approaches for fracture reduction and implant application,
including patients with subtrochanteric, high-energy intertrochanteric,
periprosthetic, and intra-articular distal femur fractures.

Exclusion Criteria:

- Preoperative use of any anticoagulant

- History of deep venous thrombosis or pulmonary embolus

- Allergy to TXA

- Hepatic dysfunction (AST/ALT > 60)

- Renal dysfunction (Cr > 1.5 or GFR < 30)

- History of cerebrovascular accident in the past 12 months

- Active coronary artery disease (event in the past 12 months)

- Presence of drug-eluting stent

- Color blindness

- Presence of an additional acute injury that could contribute to blood transfusion
requirements